Startup Spotlight: RefleXion Medical’s radiotherapy systems

Hayward, California-based therapeutic oncology firm RefleXion Medical is developing biology-guided radiotherapy treatments for cancer care.

RefleXion has raised over $320mn since its founding in 2009. Its latest Series D round, taking place last month, saw the company raise $100mn from lead investor PSP Investments, alongside Venrock, The Rise Fund, T. Rowe Price, Sofinnova Partners, Pfizer Venture Investments, KCK and Johnson & Johnson Innovation.

“RefleXion’s bold vision for the future of cancer care stands to completely reshape how physicians think about treating patients with stage 4 cancer,” said Loïc Julé, managing director, Global Investment Partnerships Portfolio, PSP Investments, in a press release. “This is exactly the mindset of companies we strive to build long-term relationships with. We are thrilled to support RefleXion during this next phase of their growth as they ramp up market and clinical adoption of this groundbreaking technology.”

SEE ALSO:

• Startup Spotlight: LetsGetChecked plans home COVID-19 tests

• Startup Spotlight: Grail’s blood test for cancer

• Startup Afya Rekod launches AI data platform to curb COVID-19

• Read the latest issue of Healthcare Global here

The company’s RefleXion X1 machine uses biology-guided radiotherapy (BgRT) to treat tumours at all stages of cancer. The company says it is designed to overcome existing technological restrictions that limit radiotherapy to one or two tumours. It is also able to treat rapidly moving tumours caused by breathing or digestion. RefleXion’s machine recently won FDA approval for certain types of radiotherapy.

Todd Powell, President and CEO of RefleXion, said: “This new influx of capital continues our momentum initiated first by FDA clearance of the RefleXion™ X1 platform last month, then quickly followed by the close of our first system order at one of the world’s leading cancer centers.The support of this top-tier investment syndicate enables us to further scale operations around commercializing the X1 platform.

“Moreover, these funds allow us to validate the practical implications of using BgRT on a daily basis as we transform radiotherapy from early-stage cancer treatment to an option for patients with all stages of cancer”.